Name: Name:Tg 100801
Brand: AABLOCKS
SKU: AA00GU46
Rating: 90 (10 reviews)

Catalog No.: AA00GU46

867331-82-6 | Tg 100801

Pack Size： 2mg

Purity： 100%

1 week

$198.00 $139.00

Pack Size： 5mg

Purity： 98%

1 week

$447.00 $313.00

Pack Size： 10mg

Purity： 98%

1 week

$685.00 $480.00

Pack Size： 25mg

Purity： 98%

1 week

$1,320.00 $924.00

Pack Size： 50mg

Purity： 98%

1 week

$2,035.00 $1,424.00

Pack Size： 100mg

Purity： 98%

1 week

$2,987.00 $2,091.00

Quantity

- +

Add to Card

Order Now

bulk Quotation Request

Technical Information

Catalog Number: AA00GU46

Chemical Name: Tg 100801

CAS Number: 867331-82-6

Molecular Formula: C33H30ClN5O3

Molecular Weight: 580.0760

MDL Number: MFCD16038901

SMILES: Clc1ccc(cc1c1cc(C)c2c(c1)nnc(n2)Nc1ccc(cc1)OCCN1CCCC1)OC(=O)c1ccccc1

Properties

Complexity: 848

Covalently-Bonded Unit Count: 1

Defined Atom Stereocenter Count: 0

Defined Bond Stereocenter Count: 0

Formal Charge: 0

Heavy Atom Count: 42

Hydrogen Bond Acceptor Count: 8

Hydrogen Bond Donor Count: 1

Isotope Atom Count: 0

Rotatable Bond Count: 10

Undefined Atom Stereocenter Count: 0

Undefined Bond Stereocenter Count: 0

XLogP3: 7

Literature fold

Title: SU5416 induces premature senescence in endothelial progenitor cells from patients with age-related macular degeneration.

Journal: Molecular vision20110101

Title: Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema.

Journal: Journal of cellular physiology20080701

Title: Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration.

Journal: Journal of medicinal chemistry20080327

Title: Palanki MS, et al. Development of prodrug 4-chloro-3-(5-methyl-3-{-(2-pyrrolidin-1-ylethoxy)phenylamino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration. J Med Chem. 2008 Mar 27;51(6):1546-59.

Title: Doukas, John, et al. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. Journal of Cellular Physiology (2008), 216(1), 29-37.